Bigard M A, Delchier J C, Riachi G, Thibault P, Barthelemy P
Department of Gastroenterology, Hospital Brabois, Nancy, France.
Aliment Pharmacol Ther. 1998 Apr;12(4):383-8. doi: 10.1046/j.1365-2036.1998.00315.x.
Triple therapy based upon omeprazole, amoxycillin and clarithromycin for 7 days is the reference treatment used in France for the eradication of Helicobacter pylori. However, optimal dosages of omeprazole and clarithromycin have not been determined.
To compare four eradication regimens using this treatment in patients with non-ulcer dyspepsia.
Two hundred and seventy-four patients with symptoms of dyspepsia, normal upper GI endoscopy and a positive urease test were included in the study. A 13C-urea breath test (UBT) was obtained before and 6 weeks after treatment. Patients were randomized to one of the following 7-day regimens: 20 mg omeprazole o.m. plus amoxycillin 1000 mg b.d. plus clarithromycin 250 mg b.d. (O20AC500) or 20 mg omeprazole o.m. plus amoxycillin 1000 mg b.d. plus clarithromycin 500 mg b.d. (O20AC1000) or 20 mg omeprazole b.d. plus amoxycillin 1000 mg b.d. plus clarithromycin 250 mg b.d. (O40AC500) or 20 mg omeprazole b.d. plus amoxycillin 1000 mg b.d. plus clarithromycin 500 mg b.d. (O40AC1000). Compliance was assessed by returned tablet counts. Eradication was defined as conversion from positive 13C-UBT at entry to negative 13C-UBT 6 weeks after cessation of therapy.
Two hundred and fifty-eight patients were included in the intention-to-treat (ITT) analysis. From the least to the most effective regimen, eradication rates were: O20AC1000: 60.0% (95% CI: 47.6-72.4), O20AC500: 64.1% (52.3-75.8), O40AC1000: 64.2% (52.7-75.7), O40AC500: 74.6% (64.2-85.0) (N.S.). Overall compliance was good in 92% of patients. The most frequent adverse events were diarrhoea and taste impairment, occurring mainly in the high-dose clarithromycin groups.
Eradication rates obtained in this study were lower than those expected on the basis of previously reported studies. This study supports the use of a double dose of omeprazole, although the difference between groups was non-significant, but provides no argument in favour of a high dose of clarithromycin.
基于奥美拉唑、阿莫西林和克拉霉素的三联疗法持续7天是法国用于根除幽门螺杆菌的标准治疗方法。然而,奥美拉唑和克拉霉素的最佳剂量尚未确定。
比较使用该疗法的四种根除方案在非溃疡性消化不良患者中的疗效。
274例有消化不良症状、上消化道内镜检查正常且尿素酶试验阳性的患者纳入研究。治疗前及治疗后6周进行13C-尿素呼气试验(UBT)。患者被随机分为以下四种7天治疗方案之一:20mg奥美拉唑口服,每日2次,加1000mg阿莫西林,每日2次,加250mg克拉霉素,每日2次(O20AC500);或20mg奥美拉唑口服,每日2次,加1000mg阿莫西林,每日2次,加500mg克拉霉素,每日2次(O20AC1000);或40mg奥美拉唑,每日2次,加1000mg阿莫西林,每日2次,加250mg克拉霉素,每日2次(O40AC500);或40mg奥美拉唑,每日2次,加1000mg阿莫西林,每日2次,加500mg克拉霉素,每日2次(O40AC1000)。通过回收的药片数量评估依从性。根除定义为治疗开始时13C-UBT阳性转变为治疗停止6周后13C-UBT阴性。
258例患者纳入意向性分析(ITT)。从疗效最差到最佳的方案,根除率分别为:O20AC1000:60.0%(95%CI:47.6 - 72.4),O20AC500:64.1%(52.3 - 75.8),O40AC1000:64.2%(52.7 - 75.7),O40AC500:74.6%(64.2 - 85.0)(无统计学差异)。92%的患者总体依从性良好。最常见的不良事件是腹泻和味觉障碍,主要发生在高剂量克拉霉素组。
本研究获得의根除率低于先前报道研究预期的根除率。本研究支持使用双倍剂量的奥美拉唑,尽管组间差异无统计学意义,但未提供支持高剂量克拉霉素的依据。